Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Big Is The Esketamine Market Today And What Is Its Future Size?

The size of the esketamine market has robustly expanded in the past years. The market will see an increase from $1.37 billion in 2024 to $1.51 billion in 2025, with a compound annual growth rate (CAGR) of 9.9%. The escalation witnessed during the historic period is due to a higher patient count, growing instances of mental health complications globally, enhanced comprehension of the disease condition, increasing requirement for cutting-edge treatment choices, and supportive regulatory permissions.

Expectation for the esketamine market size to witness a substantial surge in the coming years is high, with forecasts suggesting an expansion to “$2.26 billion by 2029, with a 10.7% compound annual growth rate (CAGR). This predicted escalation during the forecast period is attributed to the growing incidences of treatment-resistant depression, the escalation in research and development investment trends, the demand for intelligent healthcare infrastructure, the rising popularity of telehealth services, and the increasing adoption of esketamine as an effective treatment method. Enhancements in the forecast period are to include biotech firm partnerships with mental health organizations, the integration of robotics into healthcare applications, the prioritization of personalized medicine approaches, the use of sensor-based devices, and the probability of combination therapies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23393&type=smp

What External And Internal Drivers Are Influencing The Esketamine Market?

The escalating incidences of Treatment-Resistant Depression (TRD), which is not responsive to at least two different antidepressant medications given in the correct dosage and period, are likely to surge the expansion of the esketamine market in the future years. The growth of TRD has been attributed to the insufficient effectiveness of existing antidepressants, resulting in extended and repeated depressive stages. Esketamine assists TRD patients by offering a quick-acting solution that targets NMDA receptors, providing aid to those who don’t respond to conventional antidepressants. For instance, data from the National Institute of Mental Health (NIMH), a US federal organization, revealed that around 30% of individuals in the U.S. suffering from major depressive disorder in 2023 show resistance to standard treatments. Consequently, the escalating occurrence of treatment-resistant depression is triggering the expansion of the esketamine market.

Which Segmentation Factors Are Critical In The Esketamine Market Analysis?

The esketamine market covered in this report is segmented –

1) By Type: Oral Medications, Injection, Nasal Spray, Other Types

2) By Indication: Major Depressive Disorder, Chronic Pain, Post-Traumatic Stress Disorder, Anxiety Disorders

3) By Patient Type: Adult Patients, Pediatric Patients, Geriatric Patients

4) By Application: General Anesthetic, Treatment-Resistant Depression

5) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

Subsegments:

1) By Oral Medications: Immediate-Release Tablets, Extended-Release Tablets, Sublingual Tablets

2) By Injection: Intravenous Injection, Intramuscular Injection, Subcutaneous Injection

3) By Nasal Spray: Prescription Nasal Spray, Over-The-Counter Nasal Spray, Combination Therapy Nasal Spray

4) By Other Types: Plasmapheresis, Intravenous Immunoglobulin (IVIG) Therapy, Stem Cell Therapy

What Are The Dominant Trends Currently Seen In The Esketamine Market?

Leading entities in the esketamine market are prioritizing the creation of progressive treatment options, like monotherapy, to augment the relief from depressive symptoms beyond what can be achieved with placebos. Monotherapy is the technique of tackling a disease or a medical condition with a solitary drug or treatment, eschewing the blend of multiple therapies. In the case of Johnson & Johnson, an American pharmaceutical magnate, in January 2025, it unveiled that the U.S. Food and Drug Administration (FDA) sanctioned SPRAVATO (esketamine) for use as the sole monotherapy for adults with treatment-resistant depression (TRD). This approval, backed by clinical trial evidence, indicated that SPRAVATO can swiftly lessen depressive symptoms, with substantial progress noted within a day. This development paves the way for critical treatment alternatives for roughly 30% of people who do not respond well to conventional antidepressants, thereby sidelining the necessity for simultaneous oral medications. Despite SPRAVATO having a commendable safety record, it is dispensed under a Risk Evaluation and Mitigation Strategy (REMS) to counter possible adverse effects. This landmark achievement signals a pivotal leap forward in the treatment of TRD, sparking newfound optimism for enhanced patient recovery.

Who Are The Dominant Players In The Esketamine Market Today?

Major companies operating in the esketamine market are Cigna Corporation, Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sigma-Aldrich Corporation, Horizon Therapeutics plc, Hikma Pharmaceuticals plc, Cerecor Inc., Celon Pharma S.A., Nortec Química S.A., XWPharma Ltd., Seqens Group, SynZeal Research Pvt. Ltd., Arevipharma GmbH, Sage Therapeutics Inc., Supriya Lifescience Ltd., Clexio Biosciences Ltd., Maithri Drugs Pvt. Ltd., VistaGen Therapeutics Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/esketamine-global-market-report

Which Region Is Likely To Register The Fastest Growth In The Esketamine Market?

North America was the largest region in the esketamine market in 2024. The regions covered in the esketamine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=23393&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model